Filing Flows › Dare Bioscience (DARE) › Q4 2025
Dare Bioscience (DARE) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 26, 2026
Dare Bioscience (DARE) reported revenue of $1.0M for the fourth quarter 2025 (Q4 2025) and up 453-fold from the quarter before. Operating margin was -143.7%, net loss $1.4M (140.8% of revenue).
Dare Bioscience, Q4 2025: revenue $1.0M, operating margin -143.7%, net loss $1.4M, operating cash flow $1.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.0M | 453× | — |
| Operating profit | −$1.5M | — | — |
| Net earnings | −$1.4M | — | — |
| Operating cash flow | $1.4M | — | — |
| Free cash flow | $1.2M | — | — |
What changed
Revenue was $1.0M in Q4 2025, up 45155% from the previous quarter.
Operating costs exceeded revenue by $1.5M, an operating margin of -143.7%. The quarter ended with a net loss of $1.4M, narrower than the previous quarter's $3.6M loss.
Operating cash flow was $1.4M. Non-cash charges added back $534K of depreciation and amortization and $357K of share-based compensation. Working capital and other items added $2.0M. Capital expenditures of $207K left free cash flow of $1.2M.
Questions
What was Dare Bioscience's revenue in the fourth quarter 2025?
Dare Bioscience (DARE) reported revenue of $1.0M for the fourth quarter 2025 (Q4 2025) and up 453-fold from the quarter before.
Was Dare Bioscience profitable in the fourth quarter 2025?
Operating loss was $1.5M (-143.7% of revenue) and net loss $1.4M.
Source: Dare Bioscience 10-K on SEC EDGAR.